Prior to the FDA action, patients were required to get an infusion of rituximab the first day, followed by a pre-treatment diagnostic dose of radiolabeled indium-111 Zevalin.
Doctors are testing a variety of immune system stabilizers in diabetics, including Genentech (nyse: DNA - news - people )'s cancer drug rituximab (sold under the brand Rituxan).